Tumor Immunology – Immune System and Cancer
Tumor immunology studies how the immune system detects and fights cancer cells. It forms the scientific foundation for modern cancer immunotherapy approaches.
Things worth knowing about "Tumor Immunology"
Tumor immunology studies how the immune system detects and fights cancer cells. It forms the scientific foundation for modern cancer immunotherapy approaches.
What is Tumor Immunology?
Tumor immunology is a branch of both immunology and oncology that examines the interactions between the immune system and cancer cells. It investigates how the body recognizes and attacks malignant cells – and equally, how tumors manage to evade these defense mechanisms. Understanding these complex processes has driven revolutionary advances in cancer treatment over recent decades.
Fundamentals: Immune Surveillance and Tumor Development
The immune system possesses a natural monitoring mechanism known as immune surveillance. Specialized immune cells – including T lymphocytes, natural killer (NK) cells, and dendritic cells – recognize abnormal cells through altered surface structures called tumor antigens.
When the immune system successfully eliminates these cells early on, no tumor develops. However, when cancer cells manage to escape immune detection, the disease can progress. This process is called immune evasion.
Tumor Antigens
Tumor antigens are molecules on the surface of cancer cells that can be recognized by the immune system as foreign or altered. They are generally classified as:
- Tumor-specific antigens (TSAs): Found exclusively on tumor cells, for example neoantigens arising from gene mutations.
- Tumor-associated antigens (TAAs): Present on both tumor and normal cells, but significantly overexpressed on cancer cells.
Mechanisms of Immune Evasion
Cancer cells employ multiple strategies to escape immune destruction:
- Downregulation of MHC class I molecules, making it harder for T cells to identify the tumor cells
- Production of immunosuppressive cytokines such as TGF-beta and IL-10
- Activation of immune checkpoints (e.g., the PD-1/PD-L1 pathway), which suppress T cell activity
- Recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) into the tumor environment
Tumor Immunology as the Basis of Modern Cancer Therapies
Insights from tumor immunology have led to groundbreaking treatment strategies:
Checkpoint Inhibitors
Checkpoint inhibitors are antibodies that block immune checkpoint proteins, thereby reactivating the body's immune response against cancer cells. Well-known examples include pembrolizumab and nivolumab, which target the PD-1/PD-L1 signaling pathway.
CAR T-Cell Therapy
In CAR T-cell therapy (Chimeric Antigen Receptor T-Cell Therapy), a patient's own T cells are collected, genetically engineered to recognize specific tumor antigens, and then reinfused into the body. This approach has shown remarkable results particularly in certain blood cancers.
Cancer Vaccines
Cancer vaccines aim to sensitize the immune system against specific tumor antigens. They can be used prophylactically (e.g., HPV vaccines to prevent cervical cancer) or therapeutically to treat existing disease.
Monoclonal Antibodies
Monoclonal antibodies can bind specifically to tumor antigens, directly attacking cancer cells or flagging them for destruction by the immune system.
Tumor Immunology and the Tumor Microenvironment
The tumor microenvironment (TME) describes the complex cellular surroundings of a tumor, which include not only cancer cells but also immune cells, blood vessels, stromal cells, and various signaling molecules. This environment can be either immunosuppressive or immunostimulatory and significantly influences the success of therapy. A central focus of modern tumor immunology research is modulating the tumor microenvironment to enhance the immune response against the tumor.
Relevance for Diagnostics and Prognosis
Immunological markers are also playing an increasing role in cancer diagnostics and prognosis. For example, the density of tumor-infiltrating lymphocytes (TILs) in tumor tissue can serve as a prognostic marker. High TIL counts are associated with more favorable outcomes in certain cancer types.
References
- Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646-674.
- Chen DS, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity. 2013;39(1):1-10.
- National Cancer Institute (NCI). Immunotherapy for Cancer. U.S. Department of Health and Human Services; 2023. Available at: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categorySelf-acceptance
Meniscal lesion
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Tumor Immunology-en